COMP <GO>
TXT vs TMO // EV/EBITDA & P/E VALUATION
Textron Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TXT 7
— TMO 6
▲ EV/EBITDA & P/E VALUATION LEADER: TXT
LAST: $87.46 (+11.67%) • MKT CAP: $15.04B
valuation
10.2x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 9.30% | -0.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 10.2x | 30.4x | -20.20 | TXT | /valuation <GO> |
| Free Cash Flow Yield | 4.29% | 2.40% | +1.89 | TXT | /fcf-yield <GO> |
| Operating Margin | 7.60% | 17.40% | -9.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.20% | 15.10% | -8.90 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 3.90% | +4.10 | TXT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.12% | 0.24% | -0.12 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.58 | 4.50 | -1.92 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | TXT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.1 | 62.9 | +9.20 | TXT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | TXT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.2x | 36.3x | -21.10 | TXT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.04B | $262.22B | -$247.18B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXT REV | TMO REV | TXT GROSS % | TMO GROSS % | TXT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.80B | $44.56B | — | — | $646.0M | $6.29B |
| FY 2024 | $13.70B | $42.88B | — | — | $397.4M | $7.27B |
| FY 2023 | $13.68B | $42.86B | — | — | $650.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXT // BETA 1.00
TMO // BETA 0.94